{"product_id":"pulmonary-arterial-hypertension-9780470059722","title":"Pulmonary Arterial Hypertension","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cul\u003e \u003cli\u003eFirst book dedicated to this disease, previously thought to be incurable, but with the advent of new drugs, now amenable to management and a much improved prognosis for patients\u003c\/li\u003e \u003cli\u003eFrom the PAH Association, the leading experts in field\u003c\/li\u003e \u003cli\u003eIncorporates the latest AACP management guidelines\u003c\/li\u003e \u003cli\u003eIncludes evidence-based treatment algorithms based on the recently updated ACCP Guidelines for Medical Treatment\u003c\/li\u003e \u003cli\u003eAimed at specialists in pulmonology and cardiovascular disease, this volume provides the clinician with the most up to date information on the effective management of PAH\u003c\/li\u003e \u003c\/ul\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cb\u003ePreface\u003c\/b\u003e  \u003cp\u003e\u003cb\u003eContributors.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Introduction\u003c\/b\u003e (\u003ci\u003eRobyn J. Barst\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Diagnosis and assessment of pulmonary arterial hypertension\u003c\/b\u003e (\u003ci\u003eMichael D. McGoon, Adam Torbicki and Ronald J. Oudiz\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e2.1 Hemodynamics of pulmonary hypertension.\u003c\/p\u003e \u003cp\u003e2.2 Venice classification.\u003c\/p\u003e \u003cp\u003e2.3 Overview of the diagnostic process (algorithm).\u003c\/p\u003e \u003cp\u003e2.4 Screening (identifying a pre-existing risk).\u003c\/p\u003e \u003cp\u003e2.5 Detection (discovering pulmonary hypertension).\u003c\/p\u003e \u003cp\u003e2.6 Definition (diagnosing the clinical context).\u003c\/p\u003e \u003cp\u003e2.7 Prediction (estimating prognosis).\u003c\/p\u003e \u003cp\u003e2.8 Principles of follow-up (evaluating and responding to outcome).\u003c\/p\u003e \u003cp\u003e2.9 Specific tests in the evaluation of pulmonary hypertension.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Conventional therapy in pulmonary arterial hypertension\u003c\/b\u003e (\u003ci\u003eRichard N. Channick\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e3.1 Calcium channel antagonists.\u003c\/p\u003e \u003cp\u003e3.2 Diuretics.\u003c\/p\u003e \u003cp\u003e3.3 Warfarin.\u003c\/p\u003e \u003cp\u003e3.4 Supplemental oxygen.\u003c\/p\u003e \u003cp\u003e3.5 Inotropic therapy.\u003c\/p\u003e \u003cp\u003e3.6 General measures.\u003c\/p\u003e \u003cp\u003e3.7 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Prostanoid treatment for pulmonary arterial hypertension\u003c\/b\u003e (\u003ci\u003eOlivier Sitbon and Gérald Simonneau\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e4.1 Epoprostenol.\u003c\/p\u003e \u003cp\u003e4.2 Treprostinil.\u003c\/p\u003e \u003cp\u003e4.3 Iloprost.\u003c\/p\u003e \u003cp\u003e4.4 Beraprost.\u003c\/p\u003e \u003cp\u003e4.5 Treatment selection.\u003c\/p\u003e \u003cp\u003e4.6 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Endothelin receptor antagonists in pulmonary arterial\u003c\/b\u003e \u003cb\u003ehypertension\u003c\/b\u003e (\u003ci\u003eDavid B. Badesch and Marc Humbert\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e5.1 Bosentan.\u003c\/p\u003e \u003cp\u003e5.2 Sitaxsentan.\u003c\/p\u003e \u003cp\u003e5.3 Ambrisentan.\u003c\/p\u003e \u003cp\u003e5.4 Safety and tolerability with endothelin receptor antagonists.\u003c\/p\u003e \u003cp\u003e5.5 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Phosphodiesterase-5 inhibitors in pulmonary arterial hypertension\u003c\/b\u003e (\u003ci\u003eHossein A. Ghofrani, Werner Seeger and Friedrich Grimminger\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e6.1 The origins of phosphodiesterase-5 inhibitor development.\u003c\/p\u003e \u003cp\u003e6.2 Pulmonary hypertension as a new indication for phosphodiesterase-5 inhibitor treatment.\u003c\/p\u003e \u003cp\u003e6.3 Role of phosphodiesterase-5 in the pulmonary vasculature.\u003c\/p\u003e \u003cp\u003e6.4 Clinical experience with sildenafil for the treatment of chronic pulmonary hypertension.\u003c\/p\u003e \u003cp\u003e6.5 Pivotal trial and approval of sildenafil for the treatment of pulmonary arterial hypertension (SUPER-1 study).\u003c\/p\u003e \u003cp\u003e6.6 Other phosphodiesterase-5 inhibitors.\u003c\/p\u003e \u003cp\u003e6.7 Combination therapy.\u003c\/p\u003e \u003cp\u003e6.8 Potential new indications for phosphodiesterase-5 inhibitors outside pulmonary arterial hypertension.\u003c\/p\u003e \u003cp\u003e6.9 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Combination therapy for pulmonary arterial hypertension\u003c\/b\u003e (\u003ci\u003eAnne Keogh and Marius Hoeper\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e7.1 Background.\u003c\/p\u003e \u003cp\u003e7.2 Combination therapy to date.\u003c\/p\u003e \u003cp\u003e7.3 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Interventional and surgical modalities of treatment for pulmonary arterial hypertension\u003c\/b\u003e (\u003ci\u003eJulio Sandoval and Ramona Doyle\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e8.1 Introduction.\u003c\/p\u003e \u003cp\u003e8.2 Atrial septostomy.\u003c\/p\u003e \u003cp\u003e8.3 Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension.\u003c\/p\u003e \u003cp\u003e8.4 Lung transplantation for pulmonary hypertension.\u003c\/p\u003e \u003cp\u003e8.5 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 End points and clinical trial design in pulmonary arterial hypertension: Clinical and regulatory perspectives\u003c\/b\u003e (\u003ci\u003eAndrew J. Peacock\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e9.1 Introduction.\u003c\/p\u003e \u003cp\u003e9.2 Trial design.\u003c\/p\u003e \u003cp\u003e9.3 End points in trials of therapy for pulmonary arterial hypertension.\u003c\/p\u003e \u003cp\u003e9.4 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Comparative analysis of clinical trials and evidence-based treatment algorithm for pulmonary arterial hypertension\u003c\/b\u003e (\u003ci\u003eNazzareno Galiè, Alessandra Manes, Naushad Hirani and Robert Naeije\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e10.1 Introduction.\u003c\/p\u003e \u003cp\u003e10.2 Randomized controlled studies.\u003c\/p\u003e \u003cp\u003e10.3 Long-term continuation studies.\u003c\/p\u003e \u003cp\u003e10.4 Combination studies.\u003c\/p\u003e \u003cp\u003e10.5 Evidence-based treatment algorithm.\u003c\/p\u003e \u003cp\u003e10.6 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Diagnosis and assessment of non-pulmonary arterial hypertension masquerading as idiopathic pulmonary arterial hypertension: Diastolic heart failure - evaluation and interactions\u003c\/b\u003e (\u003ci\u003eMardi Gomberg-Maitland and Stuart Rich\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e11.1 Definition of heart failure.\u003c\/p\u003e \u003cp\u003e11.2 Epidemiology.\u003c\/p\u003e \u003cp\u003e11.3 Physiology.\u003c\/p\u003e \u003cp\u003e11.4 Evaluation of diastolic heart failure: Invasive and  noninvasive techniques.\u003c\/p\u003e \u003cp\u003e11.5 Diagnosis and treatment of diastolic dysfunction.\u003c\/p\u003e \u003cp\u003e11.6 Pulmonary hypertension and diastolic dysfunction.\u003c\/p\u003e \u003cp\u003e11.7 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Treatment of pulmonary arterial hypertension: A look to the future\u003c\/b\u003e (\u003ci\u003eLewis J. Rubin\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e12.1 Therapy of pulmonary arterial hypertension.\u003c\/p\u003e \u003cp\u003e12.2 Measuring outcomes and monitoring the course of therapy.\u003c\/p\u003e \u003cp\u003e12.3 Conclusions.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIndex.\u003c\/b\u003e\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49402276217175,"sku":"9780470059722","price":82.76,"currency_code":"GBP","in_stock":false}],"url":"https:\/\/bookcurl.com\/products\/pulmonary-arterial-hypertension-9780470059722","provider":"Book Curl","version":"1.0","type":"link"}